Please assess the completion status of the following clinical trial:

Trial Title: A Study of SHR6390 in Advanced Solid Tumor Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed solid tumor and failed from all standard treatment~* Eastern Cooperative Oncology Group (ECOG) performance status: 0-1~* Life expectancy ≥ 3 months~* Adequate function of major organs, meaning the following criteria should be met within 14 days before randomization:~  * Hemoglobin \> 110g/L~ * Neutrophils \> 2.0×10\^9/L~ * Platelets \> 100×10\^9/L~ * Total bilirubin \< 1.5×the upper limit of normal (ULN)~ * ALT and AST ≤ 1.5×ULN (≤ 5×ULN, if existing liver metastases)~ * Creatinine ≤ 1 ULN~ * Left ventricular ejection fraction (LVEF) ≥ 50%~ * QTcF(Fridericia correction) male≤450 ms, female≤470 ms~* Good compliance of patient by physician's judgement~* Signed and dated informed consent~Exclusion Criteria:~* Previously received therapy of anti-tumor agent targeting at CDK4/6~* Less than 3 weeks from the last cell-toxicity chemotherapy, less than 6 weeks from last mitomycin or nitrosamine therapy~* Less than 3 weeks from any other anti-tumor therapy (including targets therapy, immunotherapy or other approved therapy)~* Having joined in other clinical trials within 4 weeks~* Uncontrolled/untreated brain metastasis (well-controlled/well-treated brain metastasis by physician's judgement is allowed)~* existing abnormal CTCAE≥grade 2 resulted from previous treatment(except grade 2 alopecia)~* uncontrollable symptomatic pleural effusion or ascites or require clinical intervention~* require continous treatment by steroids~* Factors influencing the usage of oral administration (e.g. unable to swallow, chronic diarrhea and intestinal obstruction, etc.)~* existing uncontrollable hypokalemia or hypomagnesemia~* history of serious allergy events or known being allergy constitution~* active HBV or HCV infection (HBV virus≥10e4 copies/ml, HCV virus≥10e3 copies/ml)~* History of immunodeficiency, acquired or congenital immunodeficiency, history of organ transplantation~* history of cardiac dysfunction, include(1)angina (2)clinical significant arrythmia or require drug intervention (3)myocardial infarction (4)heart failure (5) other cardiac dysfunction (judged by the physician); any cardiac or nephric abnormal ≥grade 2 found in screening~* Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test childbearing female who refuse to accept any contraception practice~* determined by the physician, any coexisting disease might lead to life threatening complications or avoid the patients from accomplishing the treatment(e.g serious hypertension, diabetes, thyroid dysfunction,etc.)~* history of neuropathy or dysphrenia, including epilepsy and dementia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- SHR6390 (Type: EXPERIMENTAL): Each subject will receive a single dose of SHR6390 and then repeat doses following a 3 week/1 week off regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).